Furthermore, data scored from +1 to +4 as per immunostaining intensity was blinded evaluated resulting nearly identical in each treatment group, indicating no differences in the EGFR expression level in analysed tumours (Data not shown). This evidence concerns the gene EGFR and neoplasm.